Research :

Approved for 2004/2008 - Aggrenox versus clopidogrel for second stroke prevention. The Compliance Substudy for the PRoFESS trial (Boehringer Ingelheim).

Approved for 2004/2005 – Hemostatic Dysfunction in Acute Spontaneous Intracerebral Hemorrhage Role - Co-PI; PI- Wendy Ziai, MD (Johns Hopkins University)

Approved for 2004/2005 - Effect of clopidogrel and aspirin combination versus aspirin alone on platelets in patients with diabetes mellitus (PLUTO-DM Trial) (Sanofi, Bristol-Myers Squibb)

Approved for 2004/2005 – Effect of escalating doses of aspirin on platelet, inflammatory, and endothelial biomarkers in patients with coronary artery disease and metabolic syndrome Role - Co-PI; PI- Prof. Charles H. Hennekens. (Bayer)

Approved for 2004/2005 – Effect of Aggrenox, Telmisartan, their combination, and clopidogrel + aspirin on platelets in patients with diabetes mellitus. (Boehringer-Ingelheim).

Approved for 2005 - Effect of clopidogrel and aspirin combination versus aspirin alone on platelets in patients with periferal vascular disease (PLUTO-PVD Trial) (Sanofi, Bristol-Myers Squibb)

2004 - present Evaluation of the novel ADP cartridge before and after clopidogrel in patients with documented coronary artery disease (Accumetrics)

2004 – present – Fluorometric measurements of dipyridamole for human and animal R&D studies (Worldwide Core Laboratory). (Boehringer Ingelheim)

2004-present – Effects of tirofiban on surface platelet receptors expression in patients with diabetes mellitus, and those undergoing coronary interventions (Guilford)

2004 - present Evaluation of the propyl-gallate versus Verify Now™ cartridges in patients already receiving aspirin (Accumetrics)

2004 – present – Effect of protectant V on platelet – endothelial biomarkers in patients with coronary artery disease. The ARISE Platelet Substudy (Atherogenics).

2003 – 2004 – Effect of different doses of aspirin on bleeding complications. The meta-analyses of controlled clinical trials (McNeil).

2003 – present - Platelet function after different doses of CS-747 versus clopidogrel in patients undergoing coronary stenting (The JUMBO-TIMI-26 Platelet Substudy) (Lilly)

2003 – present - Assessment of the platelet response variability to clopidogrel. (Sanofi, Bristol-Myers Squibb).

2003 – present - Treatmemt of aspirin resistance with Aggrenox in patients with TIA and ischemic stroke (the in vitro study). (Boehringer Ingelheim)

2003 - present - Effects of escalating doses of valsartan (DiovanÓ) on platelets in patients with mild to moderate hypertension: Valsartan Inhibits Platelets (VIP Trial) Novartis

2003 – present - Effects of escitalopram on platelet function in humans (Lundbeck AG)

2003 - present - Effects of citalopram (CelexaÒ) versus placebo on platelets in patients with depression and coronary artery disease (CREATE) (Montreal Heart Institute)

2002 – 2004 - Effect of clopidogrel and aspirin combination versus aspirin alone on platelets in patients with ischemic stroke or TIA (Sanofi, Bristol-Myers Squibb).

2002 – 2003 - Effects of Aggrenox on platelet function in patients after TIA or stroke (AGATE), (Boehringer Ingelheim)

2002 - 2003 - Intreactions of atorvastatin and clopidogrel in patients undergoing coronary stenting (INTERACTION trial) (Pfizer).

2002 – 2003 - Effects of in vitro valsartan and it’s major metabolite valeryl – 4 hydroxy valsartan on human platelets (Novartis)

2001 – 2002 - Effect of Aggrenox versus conventional aspirin on bleeding risks, and timing of platelet inhibition (Boehringer Ingelheim)

2001- 2002 - Evaluation of the Epinephrine/iso-TRAP cartridge in arterial and venous samples in patients undergoing coronary interventions (Accumetrics)

2001- 2002 - Evaluation of the Precision of the Propyl Galat Cartridge in volunteers treated with single dose aspirin (Accumetrics,)

2001- 2002 - Evaluation of the Dual RPFA ADP Cartridge in subjects treated with clopidogrel or ticlopidine (Accumetrics, Inc.)

2001- 2002 - Evaluation of the Dual RPFA ADP/iso-TRAP Cartridge in subjects treated with integrilin, and tirofiban (Accumetrics)

2000-2002 - Effect of clopidogrel + aspirin versus aspirin alone on platelets in patients with congestive heart failure The PLUTO-CHF study (Bristol-Myers Squibb, Sanofi).

2000-2001 Effect of aerobic exercise on plasma levels of atrial natriuretic peptide and norepinephrine in patients with heart failure (Duke Clinical Research Institute).

2000-2002 - The in vitro effects of different thrombolytic agents on platelet aggregation, and surface receptor expression (Genentech, HeartDrug Research, LLC).

1999-2001 - Assesment of platelet-endothelial interactions in patients with acute myocardial infarction undergoing thrombolytic therapy with t-PA and TNK (ASSENT-II Platelet Study). (Genentech, HeartDrug Research, LLC).

1999–2000 - Assessment of platelet function with the Platelet Function Analyzer (PFA-100™) in patients with acute coronary syndromes, and after oral GP IIb/IIIa blockade (Dade-Behring, HeartDrug Research, LLC)

1999 – 2000 - Comparison of the Rapid Platelet Function Analyzer versus conventional aggregometry in patients with coronary artery disease after oral GP IIb/IIIa blockade (Accumetrics, HeartDrug Research, LLC)

1999 – 2000 - Assessment of platelet contractile force with the Platelet Analyzer in patients with acute coronary syndromes, and after oral GP IIb/IIIa blockade (Hemodine, HeartDrug Research, LLC)

1999 – present - Diagnostic utility of the platelet receptor expression by flow cytometry in patients with acute coronary syndromes, chest pain, and heart failure (Beckton – Dickinson, HeartDrug Research, LLC)

1998 - 2000 - Platelet function in patients with chronic heart failure (EPCOT trial) (Duke Clinical Research Institute, HeartDrug Research, L.L.C.).

1998 - 1999 - Effect of DMP 754-010 versus aspirin on platelet aggregation, major receptor expression, release reactions, and thrombin generation in patients with acute coronary syndromes. (DuPont )

1998 –1999 - Use of coenzyme Q10 (UbiquinoneÔ) in patients with acute coronary syndromes.(University of Copenhagen, Pharma Nord)

1998 - 1999 - Assessment of platelet activation and novel necrosis markers in patients with acute coronary syndromes (Zurich University)

1998 - 2000 - Effect of azytromycin in patients with Chlamydia pneumonie - associated coronary artery disease on endothelial function (Pfizer, University of Utah)

1998 - 2000 - Optimal timing of clopidogrel (PlavixÒ) loading regimen in patients undergoing coronary stenting. PRONTO trial. (Bristol - Myers Squibb, Sanofi).

1997 - 2003 - Effects of sertraline (ZoloftÒ) versus placebo on platelet/endothelial biomarkers in patients with depression after acute myocardial infarction (SADHART Platelet Substudy). (Pfizer)

1997 – 1998 - Effects of ReoPro and/or reteplase on platelet aggregation, GP IIb/IIIa, and P-selectin expression in patients with acute myocardial infarction (SPEED) (Centocor)

1996 – 1998 - Crossreactivity of the major platelet surface receptors between humans and Yorkshire swine (DAKO)

1997 – 1998 - Diagnostic utility of platelet and soluble P-selectin in patients with acute coronary syndromes. MAPS-1 trial. (Centocor)

1996- 1997 - Effects of Orbofiban on major surface platelet receptors rather than GP IIb/IIIa in patients with stabilized ischemic syndromes (Searle)

1996-1997 - Effect of r-PA vs. t-PA on the platelet status in patients with myocardial infarction. The GUSTO-III Platelet Substudy. (Boehringer Mannheim).

1992-1995 - Cardiovascular applications of leumedins (Scios - Nova)

1992- 1996 - Effect of ubiquinone (CoQ10 ®) on myocardial reperfusion injury, infarct size and platelet function. (Pharma Nord)

1993- 1996 - Coronary endothelin - I level in patients with unstable angina (Merck)

1993-1995 - Alteplase® vs. Abbokinase® vs. BM. 06.022 on platelet function and coagulation during myocardial infarction (Abbott)

1991-1992 - Genetic alterations in human complement alleles in children with nephropathies and their families (Bristol-Myers Squibb )

1986-1988 - Effects of pentoxyphilline (Trental ®) on renal function and hemorheology in children with nephrotic syndrome. (Bayer)

1984-1988 - Management of hypertension with captopril (Capoten ®) therapy in pregnant women with preeclampsia. (Squibb & Sons)